Method for producing a recipient-specific tissue transplant or tissue implant

• US 20040028662A1
• Filed: 04/01/2003
• Published: 02/12/2004
• Est. Priority Date: 05/29/2000
• Status: Active Grant

• Current Assignee: Augustinus Bader
• Original Assignee: Augustinus Bader
• Inventors: Bader, Augustinus
• Granted Patent: US 7,915,038 B2
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/383 Nerve cells, e.g. dendritic cells, Schwann cells
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3895 using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
• CPC Class Codes: C12N 5/0062 General methods for three-dimensional culture

Abstract

The method represents a further development of a cell-colonisation process, according to which biological cells are colonised on an synthetic or natural tissue matrix in order to obtain a tissue implant or tissue transplant. The growth of the cells, which in general come from the designated recipient of the transplant of implant, is frequently promoted by the addition of mediators, factors or co-factors. According to the inventive method, the factors or mediators are supplied by co-cultivating cells, which are particularly suitable for producing said factors, with the tissue.

Claims

1. A method for preparing a recipient-specific tissue transplant or tissue implant composed of a tissue matrix and recipient-tolerated cells which have colonized it, characterized in that the colonization of the tissue matrix with the recipient-tolerated cells is carried out with the participation of additional cells which produce, and release into the environment, mediators, factors or cofactors which promote tissue regeneration.

2. The method as claimed in claim 1, characterized in that the cells release inflammation-inducing mediators or factors.

3. The method as claimed in claim 1 or 2, characterized in that the cells which release mediators or factors comprise autologous cells from the transplant recipient, in particular leukocytes, dendritic cells or macrophages, or mixtures of these cells.

4. The method as claimed in one of claims 1 to 3, characterized in that the cells which release mediators or factors comprise precursor cells or stem cells.

5. The method as claimed in one of claims 1 to 4, characterized in that, during the colonization, the cells which release mediators or factors are supplied at least occasionally to a culture medium which is used for the colonization and/or to the tissue matrix.

6. The method as claimed in claim 5, characterized in that the supply is effected by adding the transplant or implant recipient'"'"'s own blood or constituents of the transplant or implant recipient'"'"'s own blood.

7. The method as claimed in claim 5 or 6, characterized in that the cells which release mediators or factors are maintained in a culture which, during the colonization, is connected to the tissue such that mediators/factors released by the culture containing the cells are supplied to the tissue during the colonization.

8. The method as claimed in claim 7, characterized in that, during the colonization or treatment with recipient-tolerated cells, the culture containing the cells which release mediators or factors, preferably a macrophage culture, is kept separate from the culture medium by means of a film, membrane or partition which is permeable for the cell mediators and/or factors, and the mediators and/or factors which are formed are released continuously into the tissue transplant culture medium.

9. The method as claimed in one of claims 1 to 8, characterized in that the tissue matrix employed is a synthetic tissue matrix.

10. The method as claimed in claim 9, characterized in that the tissue matrix employed comprises one or more of the following materials:

polyglactide, polydioxanone, biologically degradable polyesters, polyurethanes, polyacrylics, collagen and fibrinogen.

11. The method as claimed in one of claims 1 to 8, characterized in that the tissue matrix employed is a native or acellularized xenogenic or allogenic tissue matrix.

12. The method as claimed in one of claims 1 to 11, characterized in that the recipient-tolerated cells employed are autologous cells derived from the transplant or implant recipient.

13. The method as claimed in one of claims 1 to 11, characterized in that the recipient-tolerated cells employed are allogenic cells or genetically altered allogenic cells which have been selected as being tolerable for the recipient.